US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
60

600223.SS

$5.52
Sharia status
NOT COMPLIANT
Per In-house ratio engine · assessed 2026-08-26
HTR non-permissible income 1.27%
🕌Open research, not a fatwa — verify with your own scholar.
Trade setup SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Lushang Freda Pharmaceutical Co.,Ltd. (600223.SS) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

Market & analysts
Price target
$8.03
+45.5% · 3 analysts
Institutional own.
0.8%
of shares
NON-COMPLIANT
Sharia compliance
1.27%
Non-permissible income — HTR, from filings (2025-12-31)
$8.03
Price target (+45.5%) · 3 analysts
0.8%
Institutional ownership

🕌 In-house Compliance Research

Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 600223.SS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail

RatioValueThresholdResult
Interest-bearing debt 2.28% 30.00% Pass
Interest-bearing investments 46.81% 30.00% Fail
Non-permissible income 1.27% 5.00% Pass

Usmani Fail

RatioValueThresholdResult
Interest-bearing debt 2.41% 33.00% Pass
Interest-bearing investments 49.42% 33.00% Fail
Non-liquid assets 43.34% at least 20.00% Pass
Non-permissible income 1.27% 5.00% Pass

MSCI Fail

RatioValueThresholdResult
Interest-bearing debt 2.41% 33.33% Pass
Cash + interest-bearing securities 49.42% 33.33% Fail
Accounts receivable 56.66% 33.33% Fail
Non-permissible income 1.27% 5.00% Pass

FTSE Fail

RatioValueThresholdResult
Interest-bearing debt 2.41% 33.33% Pass
Cash + interest-bearing securities 49.42% 33.33% Fail
Accounts receivable 56.66% 50.00% Fail
Non-permissible income 1.27% 5.00% Pass

Dow Jones Islamic Market Fail

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.79% 33.00% Pass
Cash + interest-bearing securities 36.69% 33.00% Fail
Accounts receivable 5.38% 33.00% Pass
Non-permissible income 1.27% 5.00% Pass

S&P Shariah Pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.69% 33.00% Pass
Cash + interest-bearing securities 34.63% 49.00% Pass
Accounts receivable 5.07% 49.00% Pass
Non-permissible income 1.27% 5.00% Pass

MSCI M-Series Fail

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 1.69% 33.33% Pass
Cash + interest-bearing securities 34.63% 33.33% Fail
Accounts receivable 39.70% 49.00% Pass
Non-permissible income 1.27% 5.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

8.137.336.525.714.912025-09-112026-03-192026-09-11

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
5.51
S2
5.57
S1
5.62
PIVOT
5.68
R1
5.73
R2
5.79
R3
5.84

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

7-day expected range
5.19132 6.12868
±8.28% from 5.66, made 2026-09-10 · resolves 2026-09-17
STRONG SELL
from 19 indicators
Not enough resolved predictions yet — 0 of 10 needed before we publish an accuracy figure. 22008 forecast(s) are currently open and will be scored automatically when their horizon expires.

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

Technical Summary

STRONG SELL
19 indicators
OscillatorsSELL
2 buy · 2 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)44.80NEUTRAL
Stochastic %K (14)9.80BUY
CCI (20)-91.47NEUTRAL
Williams %R (14)-90.20BUY
MACD (12,26,9)-0.02SELL
ROC (10)-4.00SELL
Momentum (10)-0.23SELL
EMA (10)5.67SELL
SMA (10)5.68SELL
EMA (20)5.65SELL
SMA (20)5.66SELL
EMA (30)5.63SELL
SMA (30)5.64SELL
EMA (50)5.64SELL
SMA (50)5.55SELL
EMA (100)5.84SELL
SMA (100)5.74SELL
EMA (200)6.47SELL
SMA (200)6.47SELL

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

About Lushang Freda Pharmaceutical Co.,Ltd.

Real Estate · Real Estate - Development

Lushang Freda Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of cosmetics, pharmaceuticals, raw materials, and additives in China. It is involved in property management services. The company provides facial cleansers, lotions, creams, sprays, masks, and other products. It also offers products in the field of dermatology, orthopedics, ophthalmology, gynecology, and pediatrics, respiratory, endocrinology, andrology, tonic, and plasters, as well as hyaluronic acid and its derivatives, bio-fermentation, plant extracts, chemical synthesis, tablets, capsules, drinks, injections, granules, and other products. The company offers its products through online and offline channels. It exports its products to North America, the European Union, Japan, South Korea, and Southeast Asia. The company was formerly known as Lushang Health Industry Development Co.,Ltd. and changed its name to Lushang Freda Pharmaceutical Co.,Ltd. in April 2023. The company was founded in 1993 and is based in Jinan, China. Lushang Freda Pharmaceutical Co.,Ltd. is a subsidiary of Shandong Commercial Group Co.,Ltd.

lshfreda.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Not enough price history yet for a smart-money structure read on any timeframe.

Momentum & Volume

Peer Movement

Peer movement computing — it will appear here on its own.

Insider Activity (90d)

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

NEUTRAL   report date 2026-09-01 · Asset managers net 934180 (-19048)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.